表紙
市場調查報告書
商品編碼
704953

全球異位性皮膚炎市場:成長,趨勢,及預測(2020年∼2025年)

Atopic Dermatitis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球異位性皮膚炎市場成長中,尤其是起因於食物的過敏反應的異位性皮膚炎的負擔增大是主要原因之一。還有含臨床開發高級階段的產品的豐富產品研發線,支援異位性皮膚炎研究的政府資金增加,提高異位性皮膚炎的認識的宣傳活動增加等,帶動該市場的成長。

本報告提供全球異位性皮膚炎市場的相關調查,市場機會和趨勢,成長及阻礙因素,各藥物類別、投藥類型、處方類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 食物過敏造成的過敏反應的負擔增加
    • 異位性皮膚炎相關政府支出的增加
    • 提高異位性皮膚炎的認識的宣傳活動增加
  • 市場阻礙因素
    • 由於治療的費用變動造成的患者進入限制
    • 有關特定治療藥的嚴重副作用
  • 波特的五力分析

第5章 市場區隔

  • 各藥物類別
    • 皮質類固醇
    • 皮膚軟化劑/保濕劑
    • IL-4及PDE4抑制劑
    • Calcineurin抑制劑
    • 抗生素
    • 其他
  • 各投藥類型
    • 局部
    • 口服
    • 注射
  • 處方類型
    • 商店(OTC)
    • 處方
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbvie Inc.
    • Allergan PLC
    • Bausch Health Companies Inc.
    • GlaxoSmithKline PLC
    • Encore Dermatology Inc.
    • Nestle
    • LEO Pharma A/S
    • Novartis International AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 62899

The atopic dermatitis market is expected to grow at a CAGR of 7.8% during the forecast period of study during 2021-2026.

Allergy plays a significant role in patients with atopic dermatitis. The disease mostly flares up when the patient is around things that cause allergic reactions. It is particularly common in infants, as well as children, and is estimated to account for about 10-20% for those having eczema, as mentioned under the American College of Allergy, Asthma and Immunology.

Food allergy has been essentially highly debatable for decades in atopic dermatitis, with some common food, including milk, egg, and soy. There is a lot of literature that provides pieces of evidence that common food exacerbate atopic dermatitis. The malfunction in the immune system of the human body due to asthma is also among the major causes of atopic dermatitis.

Additionally, skin irritants occur due to certain soaps, detergents, perfumes, etc. Thus, allergic reactions, particularly due to food, are one of the major factors that are increasing the burden of atopic dermatitis and driving market growth.

Other factors driving the market are the rich pipeline portfolio, with products in advanced stages of clinical development, increasing government funds to support research for this disease, and rising campaigns to raise eczema awareness.

Key Market Trends

Corticosteroids Segment Dominated the Overall Market

  • Corticosteroids are referred to as cortisone-like medicines that are used as pain relief medication for inflammation in the body. These drugs are known to have effects, such as reduced itching, swelling, allergic reactions, and redness.
  • Additionally, these drugs are used as first-line treatment for different diseases, such as skin problems, severe allergies, arthritis, and asthma. Around 30 corticosteroid compounds have been licensed for atopic dermatitis treatment, of which hydrocortisone is considered to be the first.
  • The rising innovations have led to the advent of counterfeit medicines and alternative drugs, such as immuno-modulators pimecrolimus and tacrolimus. However, these alternatives have pitfalls, such as selective effectivity and high cost. Hence, topical corticosteroids play a vital role in atopic dermatitis treatment.

North America Captured the Largest Market Share and is Expected to Retain its Dominance

  • North America is expected to provide high business for the atopic dermatitis market, over the forecast period.
  • The factors, such as high treatment awareness among the patient population across the United States and Canada, healthcare infrastructure, early adoption of novel medications, better reimbursement policies, and increasing business partnerships of pharmaceutical companies with contract research organizations in the emerging markets, help the lucrative nature of this market in North America.
  • Although both countries deal with heavy healthcare expenditure, there is an increasing number of campaigns organized each year by certain foundations, such as the PAN Foundation, National Eczema Associations, and several pharmaceutical companies, along with grants.

Competitive Landscape

The presence of major market players, such as Pfizer Inc., Novartis International AG, Allergan PLC, and Abbvie Inc., is increasing the overall competitive rivalry of the market studied. Large organizations rely heavily on advertising expenses and branding strategies. They are also collaborating with successful personalities, initiatives, or programs at the national levels, which promote their product, thereby, are recognized earlier than other brands in the market studied.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Allergic Reactions with Major Role of Food Allergy
    • 4.2.2 Increasing Environmental Pollution
  • 4.3 Market Restraints
    • 4.3.1 Serious Adverse Effects Related to Certain Therapeutic Drugs
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Corticosteroids
    • 5.1.2 Emollients/Moisturizers
    • 5.1.3 IL-4 and PDE4 Inhibitors
    • 5.1.4 Calcineurin Inhibitors
    • 5.1.5 Antibiotics
    • 5.1.6 Other Drug Classes
  • 5.2 By Route of Administration
    • 5.2.1 Topical
    • 5.2.2 Oral
    • 5.2.3 Injectable
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie Inc.
    • 6.1.2 Allergan PLC
    • 6.1.3 Bausch Health Companies Inc.
    • 6.1.4 Encore Dermatology Inc.
    • 6.1.5 GlaxoSmithKline PLC
    • 6.1.6 Nestle SA
    • 6.1.7 Novartis International AG
    • 6.1.8 Pfizer Inc.
    • 6.1.9 Regenron Pharmaceutical Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS